Tierney Kathryn D, Facione Noreen, Padilla Geraldine, Blume Karl, Dodd Marylin
Stanford University Medical Center, Stanford, CA, USA.
Eur J Oncol Nurs. 2007 Sep;11(4):298-308. doi: 10.1016/j.ejon.2006.10.009. Epub 2006 Dec 28.
The purpose of this cross-sectional descriptive study is to define sexual dysfunction and menopausal symptoms in women following cytotoxic or immunosuppressive medication for the treatment of malignant or life-threatening hematolymphoid diseases. These women were preparing to undergo hematopoietic cell transplantation (HCT) as the next step in their treatment plan. It is assumed that sexual dysfunction and symptoms of premature menopause are more pronounced post-HCT due to the intensity of the preparative regimen on the hypothalamic-pituitary-gonadal axis. This study included 48 pre-menopausal women and 28 spouses/partners. Data were collected using five self-report instruments (demographic and medical, the Female Sexual Function Index, the Menopause-specific Quality of Life, the Psychosocial Adaptation to Illness Scale, and a global quality of life score). The main research variables were female sexual functioning, symptoms of menopause, and quality of life. The findings indicate that 73% of women report decreased libido and 48% report dissatisfaction with their overall sex life. Hot flashes, the most common symptom of menopause are reported by 46% and 27% report the hot flashes moderate to severe in intensity. Vaginal dryness was reported by 35% with 23% reporting the vaginal dryness to be moderate to severe. The mean quality of life (QOL) score in women was 69+/-25 with a range of 2-100 (on a scale of 0-100 with 100 being an excellent QOL). The findings indicate that women treated with standard dose chemotherapy and immunosuppressive therapy for malignant and life-threatening hematolymphoid diseases experience alterations in sexual health and symptoms of premature menopause. The results show that the desire, arousal, and orgasm phase of the sexual response cycle are altered. Additionally, nearly half of the women are experiencing hot flashes, the most common symptom of menopause and over a third report vaginal dryness. There are statistically significant correlations between altered sexual health, menopausal symptoms, and QOL scores.
这项横断面描述性研究的目的是确定接受细胞毒性或免疫抑制药物治疗恶性或危及生命的血液淋巴系统疾病的女性的性功能障碍和更年期症状。这些女性正准备接受造血细胞移植（HCT）作为其治疗计划的下一步。据推测，由于预处理方案对下丘脑 - 垂体 - 性腺轴的影响强度，性功能障碍和过早绝经症状在造血细胞移植后更为明显。本研究纳入了48名绝经前女性和28名配偶/伴侣。使用五种自我报告工具（人口统计学和医学信息、女性性功能指数、更年期特定生活质量、疾病心理社会适应量表以及总体生活质量评分）收集数据。主要研究变量为女性性功能、更年期症状和生活质量。研究结果表明，73%的女性报告性欲下降，48%的女性对其总体性生活不满意。潮热是最常见的更年期症状，46%的女性报告有潮热症状，27%的女性报告潮热程度为中度至重度。35%的女性报告有阴道干涩，23%的女性报告阴道干涩程度为中度至重度。女性的平均生活质量（QOL）评分为69±25，范围为2 - 100（评分范围为0 - 100，100表示生活质量极佳）。研究结果表明，接受标准剂量化疗和免疫抑制治疗以治疗恶性和危及生命的血液淋巴系统疾病的女性，其性健康会发生改变，并出现过早绝经症状。结果显示，性反应周期的欲望、唤起和高潮阶段均发生了改变。此外，近一半的女性正在经历潮热，这是最常见的更年期症状，超过三分之一的女性报告有阴道干涩。性健康改变、更年期症状和生活质量评分之间存在统计学上的显著相关性。
